Literature DB >> 23882437

Sialorrhea and aspiration pneumonia: a case study.

Eileen Trigoboff1, Jeffery Grace, Herman Szymanski, Jaspinder Bhullar, Claudia Lee, Thomas Watson.   

Abstract

This case study compares two different clinical outcomes for a patient with a long-standing psychotic disorder prescribed clozapine on two occasions. During the first trial, clozapine was used at a higher dose for this patient (350-450mg/day) and included clinically significant sialorrhea, pneumonia, and pneumonia-like illnesses requiring immediate medical intervention including hospitalization. There were also patient complaints of fatigue, cough, choking, and constipation leading to poor adherence. Clozapine was discontinued when the patient withdrew his consent due to side effects, despite his awareness of its benefits, including reduction of command hallucinations and irritability. The second clozapine trial was associated with lower daily doses and therapeutic serum blood levels. The patient was actively participating in and adhering to the medication plan. A very narrow window of clozapine dose was exceeded for two days and the patient complained of hypersalivation, cough, and lethargy. He was subsequently hospitalized for a two week period to treat aspiration pneumonia. This hospitalization helped establish the ideal daily dose of clozapine for this patient and also brought the relationship between aspiration pneumonia and clozapine to the attention of the psychiatrist and medical specialist. Once the appropriate dosage for this patient was established, his psychotic and affective symptoms were controlled, he was not hampered by adverse side effects, and he started to actively participate in social and recreational activities and plans that culminated in discharge from a state psychiatric facility to a supportive community residence. It is our hope that the lessons we have learned from our shared experience with this patient will be of benefit to other clinicians and patients.

Entities:  

Keywords:  Aspiration pneumonia; clozapine; dosing; hypersalivation; sialorrhea

Year:  2013        PMID: 23882437      PMCID: PMC3719458     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN: 2158-8333


  28 in total

Review 1.  When symptoms persist: clozapine augmentation strategies.

Authors:  P Buckley; A Miller; J Olsen; D Garver; D D Miller; J Csernansky
Journal:  Schizophr Bull       Date:  2001       Impact factor: 9.306

Review 2.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 3.  Clinical profile of clozapine: adverse reactions and agranulocytosis.

Authors:  J A Lieberman; A Z Safferman
Journal:  Psychiatr Q       Date:  1992

4.  Salivary flow rate in patients with schizophrenia on clozapine.

Authors:  Samir Kumar Praharaj; Amlan Kusum Jana; Kausik Goswami; Poonam R Das; Nishant Goyal; Vinod Kumar Sinha
Journal:  Clin Neuropharmacol       Date:  2010-07       Impact factor: 1.592

Review 5.  Pharmacological interventions for clozapine-induced hypersalivation.

Authors:  Rebecca J Syed Sheriff; Katie Au; Caroline Cahill; Lorna Duggan; Yanling He; Victor Udu; Jun Xia
Journal:  Schizophr Bull       Date:  2008-05-20       Impact factor: 9.306

6.  The effect of clozapine on saliva flow rate: a pilot study.

Authors:  T Rabinowitz; F R Frankenburg; F Centorrino; J Kando
Journal:  Biol Psychiatry       Date:  1996-12-01       Impact factor: 13.382

7.  Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges.

Authors:  C VanderZwaag; M McGee; J P McEvoy; O Freudenreich; W H Wilson; T B Cooper
Journal:  Am J Psychiatry       Date:  1996-12       Impact factor: 18.112

Review 8.  A review of the use of clozapine levels to guide treatment and determine cause of death.

Authors:  Anne Stark; James Scott
Journal:  Aust N Z J Psychiatry       Date:  2012-02-10       Impact factor: 5.744

Review 9.  Management of the adverse effects of clozapine.

Authors:  C R Young; M B Bowers; C M Mazure
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

10.  Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection.

Authors:  David M Taylor; Petrina Douglas-Hall; Banke Olofinjana; Eromona Whiskey; Arwel Thomas
Journal:  Br J Psychiatry       Date:  2009-02       Impact factor: 9.319

View more
  4 in total

1.  Management of common adverse effects of antipsychotic medications.

Authors:  T Scott Stroup; Neil Gray
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

Review 2.  A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions.

Authors:  Madeleine S A Tan; Faraz Honarparvar; James R Falconer; Harendra S Parekh; Preeti Pandey; Dan J Siskind
Journal:  Psychopharmacology (Berl)       Date:  2021-01-07       Impact factor: 4.530

3.  Real-World Medication Treatment Patterns for Long-Term Care Residents with Dementia-Related Psychosis.

Authors:  Nazia Rashid; Victor Abler; Sherry Andes; Leslie Citrome
Journal:  Gerontol Geriatr Med       Date:  2021-05-31

4.  Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation.

Authors:  Maxim Kuzin; Georgios Schoretsanitis; John M Kane; Christoph Hiemke; Michael Paulzen; Ekkehard Haen
Journal:  Clin Pharmacokinet       Date:  2020-10-01       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.